caa a22 4500 47705403X CHVBK 20180405111344.0 cr unu---uuuuu 170330e19960301xx s 000 0 eng 10.1007/BF02644771 doi (NATIONALLICENCE)springer-10.1007/BF02644771 Serum procollagen type III peptide in chronic hepatitis B [Elektronische Daten] Relationship to disease activity and response to interferon-α therapy [G. Giustina, G. Fattovich, M. De Paoli, M. Guido, S. Favarato, M. Rugge, A. Alberti, A. Ruol, M. Plebani] The clinical significance of serum procollagen type III peptide, a marker of active fibrogenesis, was evaluated in 110 hepatitis B surface antigen positive patients with chronic hepatitis (32 chronic persistent hepatitis, 60 chronic active hepatitis, and 18 active cirrhosis), selected on the basis of active viral replication and biochemical activity, including 54 cases treated with interferon-α. At presentation the procollagen type III peptide level serum was above normal in 48 (44%) of the 110 patients and the median value was significantly higher than that of healthy carriers with normal transaminases and histology (P<0.000005). Semiquantitative histological evaluation showed a significant correlation between serum procollagen type III peptide levels and necrosis/inflammation in the subgroup of patients with chronic active hepatitis, but no relationship with the score of fibrosis. Among patients treated with interferon-α and with increased fibrogenic activity (indicated by high pretreatment serum levels of procollagen type III peptide), peptide levels were significantly decreased when pretreatment levels were compared with those at 12 months after therapy withdrawal, both in responders to interferon (P=0.022) and non-responders (P=0.012). However, serum procollagen type III peptide levels normalized in 75% of responders to interferon with sustained serological and histological remission of liver disease, but in only 21% of non-responders (P=0.02). These results obtained in a well-defined population suggest that serum procollage type III peptide is a better marker of active fibrogenesis and inflammation than an indicator of the extent of fibrosis, and that interferon may reduce active liver fibrogenesis in chronic hepatitis B indenpendently of its effect on viral replication. However, a consistent proportion (56%) of our chronic hepatitis B patients had normal serum procollagen type III peptide levels at presentation, thus precluding the clinical use of this marker both for diagnosis of liver injury and for monitoring the therapeutic response to interferon. Springer-Verlag, 1996 Procollagen III peptide nationallicence Chronic hepatitis B nationallicence Interferon therapy nationallicence Giustina G. Istituto di Medicina Clinica, University of Padova, Padua, Italy aut Fattovich G. Istituto di Semeiotica e Nefrologia Medica, University of Verona, Policlinico Borgo Roma, I-37134, Verona, Italy aut De Paoli M. Dipartimento di Medicina di Laboratorio, Laboratorio Centrale, University of Padova, Padua, Italy aut Guido M. Istituto di Anatomia Patologica, University of Padova, Padua, Italy aut Favarato S. Istituto di Medicina Clinica, University of Padova, Padua, Italy aut Rugge M. Istituto di Anatomia Patologica, University of Padova, Padua, Italy aut Alberti A. Istituto di Medicina Clinica, University of Padova, Padua, Italy aut Ruol A. Istituto di Medicina Clinica, University of Padova, Padua, Italy aut Plebani M. Dipartimento di Medicina di Laboratorio, Laboratorio Centrale, University of Padova, Padua, Italy aut International Journal of Clinical and Laboratory Research Springer-Verlag 26/1(1996-03-01), 33-36 0940-5437 26:1<33 1996 26 599 https://doi.org/10.1007/BF02644771 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/BF02644771 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Giustina G. Istituto di Medicina Clinica, University of Padova, Padua, Italy aut NATIONALLICENCE 700 1- Fattovich G. Istituto di Semeiotica e Nefrologia Medica, University of Verona, Policlinico Borgo Roma, I-37134, Verona, Italy aut NATIONALLICENCE 700 1- De Paoli M. Dipartimento di Medicina di Laboratorio, Laboratorio Centrale, University of Padova, Padua, Italy aut NATIONALLICENCE 700 1- Guido M. Istituto di Anatomia Patologica, University of Padova, Padua, Italy aut NATIONALLICENCE 700 1- Favarato S. Istituto di Medicina Clinica, University of Padova, Padua, Italy aut NATIONALLICENCE 700 1- Rugge M. Istituto di Anatomia Patologica, University of Padova, Padua, Italy aut NATIONALLICENCE 700 1- Alberti A. Istituto di Medicina Clinica, University of Padova, Padua, Italy aut NATIONALLICENCE 700 1- Ruol A. Istituto di Medicina Clinica, University of Padova, Padua, Italy aut NATIONALLICENCE 700 1- Plebani M. Dipartimento di Medicina di Laboratorio, Laboratorio Centrale, University of Padova, Padua, Italy aut NATIONALLICENCE 773 0- International Journal of Clinical and Laboratory Research Springer-Verlag 26/1(1996-03-01), 33-36 0940-5437 26:1<33 1996 26 599 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer